

## 2014 Alliance Group Meeting Committee Chair Agenda Form

|                     |   |
|---------------------|---|
| Committee           | LEUKEMIA / LEUKEMIA CORRELATIVE SCIENCES          |
| Meeting Date / Time | Saturday, May 10, 2014 8A-1230 P                  |
| Chair(s)            | Richard M. Stone, MD; Guido Marucci, MD           |
| Vice Chair(s)       | John Byrd, MD, Tom Shea, MD, Wendy Stock, MD, PhD |

| Agenda Item / Talk / Workshop                  |  |
|--|--|
| Brief Description<br><i>(where applicable)</i> | Overview Talks (15 min talk, 10 min questions) |

|  |   |
|--|---|
| <b>Title</b>   | <b>The NCI's National Clinical Trials Network- A New Era:<br/>Where do we go from here in Leukemia?</b> |
| <b>Speaker's Full Name / Credentials</b><br><i>(i.e., Jane Doe, MPH, MD)</i> | Richard M. Stone MD   |

|  |   |
|--|---|
| <b>Title</b>   | <b>The closure of Cooperative Group Tissue Bank Studies:<br/>Where do we go from here in Leukemia Correlative<br/>Sciences?</b> |
| <b>Speaker's Full Name / Credentials</b><br><i>(i.e., Jane Doe, MPH, MD)</i> | Guido Marcucci, MD  |

|  |   |
|--|---|
| <b>Title</b>   | <b>Intergroup Collaboration in Leukemia in the NCTN Era:<br/>How do we effectively share a smaller pie?</b> |
| <b>Speaker's Full Name / Credentials</b><br><i>(i.e., Jane Doe, MPH, MD)</i> | Mark Litzow, MD<br>Chair. ECOG Leukemia Committee   |

## 2014 Alliance Group Meeting Committee Chair Agenda Form

| Protocol Review       |   |              |                                    |                          |
|-----------------------|---|--------------|------------------------------------|--------------------------|
| Category              | Study Title   | Study Number | Study Chair                        | Presenter's Name         |
| <b>Active</b>         | Chemo +/- blinatumumab in middle aged adults with pre-B-ALL                                 | E1910        | M . Litzow<br>M. Wieduwilt, (A)    | M. Litzow (915-930)      |
| <b>Active</b>         | Chemo +dasatinib f/b transplant for Ph+ ALL   | C10701       | M. Wetzler                         | M. Wetzler (930-940)     |
| <b>In Development</b> | Where do we go from here in PH+ALL  |              | M. Wetzler                         | M. Wetzler (940-955)     |
| <b>LSC approved</b>   | Ph Iil succesor to 10403: AYA chemo+/- inotuzumab in pre-B-ALL                              | A041303      | D. DeAngelo                        | D. DeAngelo (955-1010)   |
| <b>Approved</b>       | Ancillary Studies to A041303:MRD and LDA  | A041202      | W. Stock                           | W. Stock (1010-1020)     |
| <b>CTEP Approved</b>  | Blinatumumamab plus POMP in PH- ALL, age >70  | S1318        | A.Advani<br>TBD (A)                | R. Stone (1020-1025)     |
| <b>Active</b>         | FCR v ibrutinib in younger CLL  | E1910        | T. Shanafelt<br>J. Barientos (A)   | J. Barientos (1025-1035) |
| <b>Active</b>         | Ibrutinib v ibrutinib/rituximab v bendamustine/rituximab in older adults with untreated CLL | A041202      | J. Woyach                          | J. Woyach (1035-1045)    |
|                       |   |              |                                    |                          |
| <b>In development</b> | Designing a relapse trial in the era of New Agents in CLL                                   |              | J. Brown                           | J. Brown (1045-1100)     |
| <b>Active</b>         | Revlimid alone +/- Procrit in low or inter-1 risk MDS & symp anem                           | E2905        | A. List                            | R. Stone (1100-1105)     |
| <b>Active</b>         | Rand ph II aza+len vs aza vs aza+vorin in MDS/CMML  | S1117        | M. Sekeres<br>T. Odenike (A)       | T. Odenike (1105-1125)   |
| <b>In development</b> | Where do we go from here in MDS   |              |                                    | T.Odenike (1105-1125)    |
| <b>Active</b>         | S1203: Rnd pHIII for AML < 60: 1A & SAHA vs 1A vs 7+3 (DNR90)                               | CTSU         | G. Garcia-Manero<br>D. Rizzeri (A_ | D. Rizzeri (1125-1135)   |

## 2014 Alliance Group Meeting Committee Chair Agenda Form

|                       |   |                  |                            |  |
|-----------------------|---|------------------|----------------------------|--|
| <b>In development</b> | Chemo/dastanib/bortezomib in CBF AML                            | C10801 successor | G. Marcucci                | G. Marcucci (1135-1150)                |
| <b>In development</b> | Where do we go from here in older AML                           |                  | G. Uy, E. Attar, H. Klepin | G. Uy, E. Attar, H. Klepin (1150-1210) |
| <b>Completed</b>      | The role of maintenance rx in APL                               | C9710            | B. Powell                  | B. Powell ( 1210-1220)                 |
| <b>Completed</b>      | Re-analysis plan for C10603                                     | C10603           | R. Stone                   | R. Stone (1220-1230)                   |
|                       | <b>LEUKEMIA CORR. SCIENCES</b>                                  |                  |                            |  |
| <b>Active</b>         | The CALGB leukemia tissue bank                                  | 9665-10          | M. Caligiuri               | G . Marcucci                           |
| <b>Active</b>         | Molecular genetic features of acute leukemia                    | 9862-02          | W. Stock                   | W. Stock                               |
| <b>Active</b>         | Assessment of novel molecular markers in AML                    | 20202-02         | C. Bloomfield              | G Marcucci                             |
| <b>Active</b>         | Molecular markers of CLL  | 20203-00         | J. Byrd                    | J. Byrd                                |
| <b>Active</b>         | NK cell recognition & lysis of autologous blasts in AML pts     | 20206-00         | D. Benson                  | G. Marcucci                            |
| <b>Active</b>         | LTB: MDR protein gene polymorphisms in AML                      | 20501-01         | M. Baer                    | M. Baer                                |
| <b>Active</b>         | LTB: Molecular genetic studies of AML with normal cytogenetics  | 20502-00         | G. Marcucci                | G. Marcucci                            |
|                       | LTB: Identification of target genes for dx and prognosis of AML | 20801-00         | J. Rowley                  | G. Marcucci                            |